Unknown

Dataset Information

0

High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma.


ABSTRACT: In our previous study, we had identified SOX30 as a novel tumor suppressor that acts through direct regulation of p53 transcription in human lung cancer. Here, we sought to determine the clinical relevance of SOX30 expression in a series of surgically-resected non-small cell lung cancer (NSCLC) patients. Analysis of SOX30 expression and clinico-pathologic features reveal a significant correlation of SOX30 expression with histological type (n?=?220, P?=?0.008) and clinical stage (n?=?220, P?=?0.024). Kaplan-Meier analysis indicates an association of high SOX30 expression with better prognosis in NSCLC patients (n?=?220, P?=?0.007). Via multivariate Cox-regression analysis, SOX30 expression is revealed to be an independent prognostic factor for overall survival (OS) of NSCLC patients (n?=?220, P?=?0.014, hazard ratio (HR)?=?0.816). In particular, SOX30 is a favorable and independent prognostic factor in one main subtype of NSCLC, lung adenocarcinoma (ADC) patients (n?=?150, P?=?0.000, HR?=?0.405), but not in another main subtype of NSCLC, squamous cell carcinoma patients. Furthermore, high expression of SOX30 represents a favorable and independent factor for the prognosis of ADC patients at clinical stage II (P?=?0.013), with positive lymph node (P?=?0.003), at histological grade 2 (P?=?0.000) or grade 3 (P?=?0.025). In summary, SOX30 expression represents an important prognostic factor for survival time in ADC patients.

SUBMITTER: Han F 

PROVIDER: S-EPMC4557060 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma.

Han Fei F   Liu Wenbin W   Xiao Hualiang H   Dong Yan Y   Sun Lei L   Mao Chengyi C   Yin Li L   Jiang Xiao X   Ao Lin L   Cui Zhihong Z   Cao Jia J   Liu Jinyi J  

Scientific reports 20150902


In our previous study, we had identified SOX30 as a novel tumor suppressor that acts through direct regulation of p53 transcription in human lung cancer. Here, we sought to determine the clinical relevance of SOX30 expression in a series of surgically-resected non-small cell lung cancer (NSCLC) patients. Analysis of SOX30 expression and clinico-pathologic features reveal a significant correlation of SOX30 expression with histological type (n = 220, P = 0.008) and clinical stage (n = 220, P = 0.0  ...[more]

Similar Datasets

| S-EPMC6442995 | biostudies-literature
| S-EPMC8584041 | biostudies-literature
| S-EPMC263849 | biostudies-literature
| S-EPMC8040402 | biostudies-literature
| S-EPMC6280504 | biostudies-literature
| S-EPMC5897927 | biostudies-literature
| S-EPMC8127640 | biostudies-literature
| S-EPMC5984358 | biostudies-literature
| S-EPMC8306423 | biostudies-literature
| S-ECPF-GEOD-47056 | biostudies-other